Sign In
Buy NTLA
$13.02
-0.110 (-0.84%)
At Close: Jun 03, 2026
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a
Intellia Therapeutics - Steady Progress, Historic Commercial Approval In Sight
08:45am, Sunday, 31'st May 2026
Intellia Therapeutics remains a Buy, driven by two pivotal in vivo gene therapy catalysts: Lonvo-Z for HAE and Nex-Z for ATTR amyloidosis. Lonvo-Z's Phase 3 data met all endpoints with an 87% attack r
ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now?
03:36pm, Wednesday, 27'th May 2026
NTLA gains momentum after positive phase III data for its CRISPR therapy, while ADMA faces pricing and inventory pressure in IG markets.
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?
12:56pm, Tuesday, 19'th May 2026
NTLA advances late-stage studies for nex-z and starts FDA filing for lonvo-z, positioning its pipeline for potential long-term growth.
Intellia Therapeutics, Inc. (NTLA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
09:40pm, Tuesday, 12'th May 2026
Intellia Therapeutics, Inc. (NTLA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus
12:47pm, Tuesday, 12'th May 2026
Intellia cuts its Q1 loss, advances late-stage gene-editing programs and plans a 2027 launch for lonvo-z after strong phase III HAE data.
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Misses Revenue Estimates
09:41am, Monday, 11'th May 2026
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to a loss of $1.1 per share a year ago.
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
07:30am, Monday, 11'th May 2026
CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing an
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:01am, Thursday, 07'th May 2026
Intellia Therapeutics (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
10:12am, Wednesday, 06'th May 2026
One of these stocks plummeted 49% on Tuesday.
Intellia Therapeutics to Participate in Upcoming Investor Conferences
07:30am, Tuesday, 05'th May 2026
CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing an
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 01'st May 2026
CAMBRIDGE, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing an
Intellia Therapeutics Posts Phase 3 HAELO Win for lonvo-z, Begins Rolling FDA BLA Filing
03:13pm, Wednesday, 29'th Apr 2026
Intellia Therapeutics (NASDAQ: NTLA) highlighted top-line results from its Phase III HAELO trial evaluating lonvo-z, an investigational in vivo CRISPR-based gene-editing therapy for hereditary angioed
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
07:00am, Wednesday, 29'th Apr 2026
CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing
Cathie Wood just made a massive bet on these two top AI stocks
06:27am, Wednesday, 29'th Apr 2026
While the heyday of Cathie Wood's investment management is, for the time being, firmly in the past, the popular ARK Innovation ETF (ARKK) has been having a respectable run in the last 12 months and un
